Filing Flows

Filing Flows › 8-K events › Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals: entry into a material definitive agreement

Form 8-K filed Nov 4, 2026 · items 1.01, 2.03

Debt and financingNovember 4 , 2026

What the filing says

On November 2, 2026 (the “Closing Date”), Arrowhead Pharmaceuticals, Inc. (the “Company”) and its subsidiary, Arrowhead Madison Inc., as guarantor, refinanced its senior secured term loans under the Existing Financing Agreement (defined below) by entering into an Amended and Restated Financing Agreement (the “A&R Finan

Read the filing on SEC EDGAR →

What usually followsAcross 23,525 8-Ks reporting Item 1.01 (material definitive agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.4%, up 51% of the time); over the following 21 sessions, +1.0%. Item 2.03: 0.0% next session across 13,268. Every item ranked →

What this kind of filing means

Item 1.01 — Entry into a material definitive agreement. A material agreement is one the company considers important enough to disclose within four business days: a merger agreement, a large supply or customer contract, a credit agreement or a licence. The terms often move the company’s outlook more than a quarter’s results.

Item 2.03 — Creation of a direct financial obligation. New debt or a guarantee: the amount, the rate and the maturity set the cost of capital and the repayment wall ahead.

Arrowhead Pharmaceuticals at a glance

Latest quarterQ3 FY26
Revenue$75.3M
Revenue Y/Y+171%
Operating margin-226.0%
IndustryPharmaceutical Preparations

Arrowhead Pharmaceuticals, Q3 FY26: revenue $75.3M (+171% year over year), operating margin -226.0%. The chart follows the revenue to costs, profit and cash.

Arrowhead Pharmaceuticals: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent debt and financing

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.